{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:51:39Z","timestamp":1791435099929,"version":"4.3.3"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Hypothesis<\/jats:title>\n                    <jats:p>Some women experience their first episode of psychosis (FEP) in mid-to-later life, including around menopause. Emerging evidence suggests reduced treatment response at this time. However, menopause is rarely considered in treatment guidelines. This study examined whether women experiencing FEP after menopause were prescribed higher olanzapine doses than younger women, using age as a proxy for menopausal status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Design<\/jats:title>\n                    <jats:p>A population-based cohort of individuals aged 18\u201364 presenting with FEP to a Dublin mental health service over 18\u00a0years was analyzed. Participants who received an adequate olanzapine trial (\u22656\u00a0weeks) for FEP were included. Women were stratified by age: &amp;lt;51\u00a0years (assumed premenopausal) and\u2009\u226551\u00a0years (assumed postmenopausal). Mean maximum daily olanzapine doses were compared. Analyses were repeated in men.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Results<\/jats:title>\n                    <jats:p>Of 396 individuals presenting with FEP, 218 met inclusion criteria. Women aged \u226551 (n\u2009=\u200916) received higher olanzapine doses compared to younger women (n\u2009=\u200978) (15.3\u00a0mg\u2009\u00b1\u20096.4 vs 12.4\u00a0mg\u2009\u00b1\u20095.4; mean difference 2.9\u00a0mg, 95% CI, \u22120.10 to 5.99, one-sided P\u2009=\u2009.029, d\u2009=\u20090.53). No age-related dose differences were observed in men (n\u2009=\u2009124).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Women presenting with FEP after assumed menopause were prescribed higher olanzapine doses than younger women. This finding should be interpreted cautiously due to the small sample size and inference of menopausal status from age. However, this aligns with emerging evidence suggesting antipsychotic response may reduce following menopause. If replicated, these findings may have important clinical implications for guiding psychosis treatment in mid-life women.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/schbul\/sbag156","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:39:42Z","timestamp":1784893182000},"source":"Crossref","is-referenced-by-count":0,"title":["Olanzapine Dosing in Women with First-Episode Psychosis: An Age-Based Proxy for Menopausal Status"],"prefix":"10.1093","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2651-5764","authenticated-orcid":false,"given":"Tara","family":"Burke","sequence":"first","affiliation":[{"name":"School of Medicine, University College Dublin, Belfield, Dublin 4 ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University College Cork, Cork ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris E","family":"Sommer","sequence":"additional","affiliation":[{"name":"Center for Clinical Neuroscience and Cognition, University Medical Center Groningen, Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Keating","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Saint John of God Hospital, Stillorgan, County Dublin ,","place":["Ireland"]},{"name":"School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, 123 St Stephen\u2019s Green, Dublin 2 ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Duffy","sequence":"additional","affiliation":[{"name":"School of Medicine, University College Dublin, Belfield, Dublin 4 ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Doherty","sequence":"additional","affiliation":[{"name":"School of Medicine, University College Dublin, Belfield, Dublin 4 ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6240-6952","authenticated-orcid":false,"given":"Brian","family":"O\u2019Donoghue","sequence":"additional","affiliation":[{"name":"School of Medicine, University College Dublin, Belfield, Dublin 4 ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"2026100800431567800_ref1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41537-020-0102-z","article-title":"The clinical course of schizophrenia in women and men\u2014a nation-wide cohort study","volume":"6","author":"Sommer","year":"2020","journal-title":"NPJ Schizophr"},{"key":"2026100800431567800_ref2","doi-asserted-by":"crossref","first-page":"113804","DOI":"10.1016\/j.addr.2021.05.014","article-title":"Let\u2019s talk about sex: differences in drug therapy in males and females","volume":"175","author":"Madla","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"key":"2026100800431567800_ref3","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1080\/17425255.2025.2481891","article-title":"The influence of female sex and estrogens on drug pharmacokinetics: what is the evidence?","volume":"21","author":"Bosch","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2026100800431567800_ref4","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","article-title":"The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia","volume":"177","author":"Keepers","year":"2020","journal-title":"Am J Psychiatry"},{"key":"2026100800431567800_ref5","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/jcp.0000000000001041","article-title":"Systematic review of gender bias in the clinical trials of new long-acting antipsychotic drugs","volume":"39","author":"Santos-Casado","year":"2019","journal-title":"J Clin Psychopharmacol"},{"key":"2026100800431567800_ref6","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/01.jcp.0000236652.78168.ee","article-title":"Sex selection bias in schizophrenia antipsychotic trials","volume":"26","author":"Chaves","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"2026100800431567800_ref7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/nrn3856","article-title":"The neuroprotective actions of oestradiol and oestrogen receptors","volume":"16","author":"Arevalo","year":"2015","journal-title":"Nat Rev Neurosci"},{"key":"2026100800431567800_ref8","doi-asserted-by":"crossref","first-page":"615356","DOI":"10.1155\/2015\/615356","article-title":"A role for estrogen in schizophrenia: clinical and preclinical findings","volume":"2015","author":"Gogos","year":"2015","journal-title":"Int J Endocrinol"},{"key":"2026100800431567800_ref9","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.neubiorev.2014.06.005","article-title":"Alterations in the serotonin system in schizophrenia: a systematic review and meta-analysis of postmortem and molecular imaging studies","volume":"45","author":"Selvaraj","year":"2014","journal-title":"Neurosci Biobehav Rev"},{"key":"2026100800431567800_ref10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41582-023-00904-0","article-title":"Schizophrenia: from neurochemistry to circuits, symptoms and treatments. Nature reviews","volume":"20","author":"Howes","year":"2024","journal-title":"Neurology."},{"key":"2026100800431567800_ref11","doi-asserted-by":"publisher","first-page":"1348551","DOI":"10.3389\/fnins.2024.1348551","article-title":"The impact of estradiol on serotonin, glutamate, and dopamine systems","volume":"18","author":"Bendis","year":"2024","journal-title":"Front Neurosci"},{"key":"2026100800431567800_ref12","doi-asserted-by":"crossref","first-page":"6962","DOI":"10.1111\/ejn.16607","article-title":"Sex and estradiol effects in the rodent dorsal striatum","volume":"60","author":"Lewitus","year":"2024","journal-title":"Eur J Neurosci"},{"key":"2026100800431567800_ref13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1097\/yco.0000000000000699","article-title":"Estrogens in schizophrenia: progress, current challenges and opportunities","volume":"34","author":"Brand","year":"2021","journal-title":"Curr Opin Psychiatry"},{"key":"2026100800431567800_ref14","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1001\/jamapsychiatry.2014.16","article-title":"A comprehensive nationwide study of the incidence rate and lifetime risk for treated mental disorders","volume":"71","author":"Pedersen","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"2026100800431567800_ref15","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1017\/S1092852921000742","article-title":"Gender, age at onset, and duration of being ill as predictors for the long-term course and outcome of schizophrenia: an international multicenter study","volume":"27","author":"Fountoulakis","year":"2022","journal-title":"CNS Spectr"},{"key":"2026100800431567800_ref16","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s12888-017-1427-7","article-title":"The global prevalence of postpartum psychosis: a systematic review","volume":"17","author":"VanderKruik","year":"2017","journal-title":"BMC Psychiatry"},{"key":"2026100800431567800_ref17","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(14)61278-2","article-title":"Bipolar disorder, affective psychosis, and schizophrenia in pregnancy and the post-partum period","volume":"384","author":"Jones","year":"2014","journal-title":"Lancet"},{"key":"2026100800431567800_ref18","doi-asserted-by":"publisher","first-page":"101855","DOI":"10.1016\/j.beem.2023.101855","article-title":"Menopause: physiology, definitions, and symptoms","volume":"38","author":"Gatenby","year":"2024","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2026100800431567800_ref19","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci12101342","article-title":"The effect of menopause on antipsychotic response","volume":"12","author":"Gonz\u00e1lez-Rodr\u00edguez","year":"2022","journal-title":"Brain Sci"},{"key":"2026100800431567800_ref20","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1017\/S0033291722001143","article-title":"Risk for midlife psychosis in women: critical gaps and opportunities in exploring perimenopause and ovarian hormones as mechanisms of risk","volume":"52","author":"Culbert","year":"2022","journal-title":"Psychol Med"},{"key":"2026100800431567800_ref21","doi-asserted-by":"publisher","first-page":"114997","DOI":"10.1016\/j.psychres.2022.114997","article-title":"Gender differences in the response to antipsychotic medication in patients with schizophrenia: an individual patient data meta-analysis of placebo-controlled studies","volume":"320","author":"Storosum","year":"2023","journal-title":"Psychiatry Res"},{"key":"2026100800431567800_ref22","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00737-022-01247-3","article-title":"Sex and gender differences in symptoms of early psychosis: a systematic review and meta-analysis","volume":"25","author":"Carter","year":"2022","journal-title":"Arch Womens Ment Health"},{"key":"2026100800431567800_ref23","doi-asserted-by":"publisher","first-page":"916198","DOI":"10.1155\/2012\/916198","article-title":"Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review","volume":"2012","author":"Ochoa","year":"2012","journal-title":"Schizophr Res Treatment"},{"key":"2026100800431567800_ref24","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/nmd.0000000000000645","article-title":"Sex differences in psychiatric hospitalizations of individuals with psychotic disorders","volume":"205","author":"Shlomi Polachek","year":"2017","journal-title":"J Nerv Ment Dis"},{"key":"2026100800431567800_ref25","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jpsychires.2025.09.067","article-title":"Hospitalization in women with psychosis: an age-based proxy analysis for menopause","volume":"191","author":"Monteiro Fernandes","year":"2025","journal-title":"J Psychiatr Res"},{"key":"2026100800431567800_ref26","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/0010-440X(83)90100-1","article-title":"Interaction of sex, age, and neuroleptic dose","volume":"24","author":"Seeman","year":"1983","journal-title":"Compr Psychiatry"},{"key":"2026100800431567800_ref27","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1097\/jcp.0000000000000571","article-title":"Antipsychotic response worsens with postmenopausal duration in women with schizophrenia","volume":"36","author":"Gonz\u00e1lez-Rodr\u00edguez","year":"2016","journal-title":"J Clin Psychopharmacol"},{"key":"2026100800431567800_ref28","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1093\/schbul\/sbac139","article-title":"Women with schizophrenia-Spectrum disorders after menopause: a vulnerable Group for Relapse","volume":"49","author":"Sommer","year":"2023","journal-title":"Schizophr Bull"},{"key":"2026100800431567800_ref29","doi-asserted-by":"crossref","first-page":"516","DOI":"10.2174\/138920010791636202","article-title":"Atypical antipsychotic metabolism and excretion","volume":"11","author":"Sheehan","year":"2010","journal-title":"Curr Drug Metab"},{"key":"2026100800431567800_ref30","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.clpt.2005.06.009","article-title":"Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2","volume":"78","author":"Granfors","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"2026100800431567800_ref31","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbaf217","article-title":"The impact of sex and age on antipsychotic serum concentrations","volume":"52","author":"de Beer","year":"2026","journal-title":"Schizophr Bull"},{"key":"2026100800431567800_ref32","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/acps.12794","article-title":"Effects of age and gender on the serum levels of clozapine, olanzapine, risperidone, and quetiapine","volume":"136","author":"Castberg","year":"2017","journal-title":"Acta Psychiatr Scand"},{"key":"2026100800431567800_ref33","doi-asserted-by":"publisher","volume":"52","journal-title":"Schizophr Bull.","DOI":"10.1093\/schbul\/sbaf186"},{"key":"2026100800431567800_ref34","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/FTD.0000000000001227","article-title":"Therapeutic drug monitoring of olanzapine: effects of clinical factors on plasma concentrations in psychiatric patients","volume":"46","author":"Ansermot","year":"2024","journal-title":"Ther Drug Monit"},{"key":"2026100800431567800_ref35","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12091362","article-title":"Racial\/ethnic differences in the pharmacokinetics of antipsychotics: focusing on east Asians","volume":"12","author":"Lin","year":"2022","journal-title":"J Pers Med"},{"key":"2026100800431567800_ref36","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","article-title":"Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology","volume":"174","author":"Howes","year":"2017","journal-title":"Am J Psychiatry"},{"key":"2026100800431567800_ref37","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3109\/13697137.2010.507886","article-title":"Age of menopause and impact of climacteric symptoms by geographical region","volume":"13","author":"Palacios","year":"2010","journal-title":"Climacteric."},{"key":"2026100800431567800_ref38","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/ajhb.1310040107","article-title":"The normal menopause transition","volume":"4","author":"McKinlay","year":"1992","journal-title":"Am J Hum Biol"},{"key":"2026100800431567800_ref39","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12905-020-00932-8","article-title":"Is menopause still evolving? Evidence from a longitudinal study of multiethnic populations and its relevance to women\u2019s health","volume":"20","author":"Chan","year":"2020","journal-title":"BMC Womens Health"},{"key":"2026100800431567800_ref40","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/jcp.0000000000001390","article-title":"Effects of dose, age, sex, body weight, and smoking on plasma concentrations of olanzapine and N-desmethyl olanzapine in inpatients with schizophrenia","volume":"41","author":"An","year":"2021","journal-title":"J Clin Psychopharmacol"},{"key":"2026100800431567800_ref41","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/00007691-200302000-00007","article-title":"Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication","volume":"25","author":"Gex-Fabry","year":"2003","journal-title":"Ther Drug Monit"},{"key":"2026100800431567800_ref42","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.phrs.2016.02.014","article-title":"Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics","volume":"106","author":"Spina","year":"2016","journal-title":"Pharmacol Res"},{"key":"2026100800431567800_ref43","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/j.1365-2125.2010.03880.x","article-title":"The effect of ethinylestradiol-containing contraceptives on the serum concentration of olanzapine and N-desmethyl olanzapine","volume":"71","author":"Haslemo","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"2026100800431567800_ref44","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1093\/ijnp\/pyad029","article-title":"Weight gain and metabolic changes in patients with first-episode psychosis or early-phase schizophrenia treated with olanzapine: a meta-analysis","volume":"26","author":"Correll","year":"2023","journal-title":"Int J Neuropsychopharmacol"},{"key":"2026100800431567800_ref45","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/S2213-8587(22)00076-6","article-title":"Menopause: a cardiometabolic transition","volume":"10","author":"Nappi","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026100800431567800_ref46","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1017\/S0033291721004591","article-title":"Antipsychotic medication for women with schizophrenia spectrum disorders","volume":"52","author":"Brand","year":"2022","journal-title":"Psychol Med"},{"key":"2026100800431567800_ref47","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1161\/CIR.0000000000000912","article-title":"Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association","volume":"142","author":"El Khoudary","year":"2020","journal-title":"Circulation."},{"key":"2026100800431567800_ref48","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s002280050445","article-title":"Polypharmacy: correlations with sex, age and drug regimen. A prescription database study","volume":"54","author":"Bjerrum","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"2026100800431567800_ref49","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/gerona\/glr118","article-title":"Drug metabolism in older people\u2014a key consideration in achieving optimal outcomes with medicines","volume":"67A","author":"McLachlan","year":"2012","journal-title":"The Journals of Gerontology: Series A"},{"key":"2026100800431567800_ref50"},{"key":"2026100800431567800_ref51","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.bbrc.2019.04.034","article-title":"CYP1A2 contributes to alcohol-induced abnormal lipid metabolism through the PTEN\/AKT\/SREBP-1c pathway","volume":"513","author":"Zhu","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"key":"2026100800431567800_ref52","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1111\/add.12599","article-title":"The impact of alcohol on clinical outcomes in established psychosis: a longitudinal study","volume":"109","author":"Barrowclough","year":"2014","journal-title":"Addiction."},{"key":"2026100800431567800_ref53","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s40262-022-01119-0","article-title":"Liver cirrhosis affects the pharmacokinetics of the six substrates of the Basel phenotyping cocktail differently","volume":"61","author":"Duthaler","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"2026100800431567800_ref54","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/schbul\/sbad058","article-title":"The direct and long-term effects of raloxifene as adjunctive treatment for schizophrenia-spectrum disorders: a double-blind, randomized clinical trial","volume":"49","author":"Brand","year":"2023","journal-title":"Schizophr Bull"},{"key":"2026100800431567800_ref55","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/acps.13530","article-title":"Estradiol and raloxifene as adjunctive treatment for women with schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials","volume":"147","author":"Li","year":"2023","journal-title":"Acta Psychiatr Scand"},{"key":"2026100800431567800_ref56","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1176\/appi.ajp.20230850","article-title":"Real-world effectiveness of menopausal hormone therapy in preventing relapse in women with schizophrenia or schizoaffective disorder","volume":"181","author":"Brand","year":"2024","journal-title":"Am J Psychiatry"}],"container-title":["Schizophrenia Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/52\/5\/sbag156\/70773059\/sbag156.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/52\/5\/sbag156\/70773059\/sbag156.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:43:50Z","timestamp":1791434630000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article\/doi\/10.1093\/schbul\/sbag156\/8769741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,8,20]]}},"URL":"https:\/\/doi.org\/10.1093\/schbul\/sbag156","relation":{},"ISSN":["0586-7614","1745-1701"],"issn-type":[{"value":"0586-7614","type":"print"},{"value":"1745-1701","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,20]]},"article-number":"sbag156"}}